Author of

• 20152

  +

  P1.03 - Chemotherapy/Targeted Therapy (ID 689)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22591

    +

    P1.03-036 - Adjuvant Chemotherapy with Uracil-Tegafur for Pathological T1aN0M0 Lung Adenocarcinoma with Lymphatic Vessel Invasion (ID 9609)

    09:30 - 09:30  |  Author(s): W. Nishio
    • Abstract
    • Slides

    Background:
    The aim of this retrospective study was to investigate the efficacy of adjuvant chemotherapy for patients in pathological T1aN0M0 lung adenocarcinoma with lymphatic vessel invasion.
    
    Method:
    We retrospectively collected data on 72 consecutive patients with pathological T1aN0M0 (the 7th edition of the UICC TNM stating system) lung adenocarcinoma with lymphatic or/and vessel invasion from January 2001 to December 2013. Adjuvant uracil-tegafur group were compared with control group. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and differences compared using log-rank test. Prognostic factors were evaluated using a Cox proportional hazard model.
    
    Result:
    Among the 72 patients, 21 patients (29.1%) were treated with adjuvant chemotherapy with uracil–tegafur. No significant difference was found in patient characteristics between the two groups. In the 21 adjuvant chemotherapy and 51 control groups, the 5-year OS rates were 100% versus 80.8%, respectively; and the 5-year DFS rates were 88.2% versus 65.1% (p=0.0138), respectively. Multivariate analysis revealed that adjuvant chemotherapy was only independent predictor of OS and DFS (p = 0.014, 0.013, respectively).
    
    Conclusion:
    Adjuvant chemotherapy with uracil–tegafur improves survival among patients with completely resected pathological T1aN0M0 lung adenocarcinoma with lymphatic vessel invasion. Our study suggests that pathological T1aN0M0 lung adenocarcinoma with lymphatic vessel invasion potentially benefits from adjuvant chemotherapy.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.